newsfilter
← Latest News
PR Newswire·

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation treatments for dermatological and...